Beacon Biosignals Funding, Investors & Competitors

Beacon Biosignals has raised $127M across 4 funding rounds, most recently a $11M Series B in April 2026.

Last Beacon Biosignals funding round

$11M

Series B · Apr 2026

Cumulative funding Beacon Biosignals raised

$127M

across 4 funding rounds

Key investors in Beacon Biosignals

  • General Catalyst
  • Casdin Capital
  • Indicator Ventures
  • GV
  • S32
  • Catalio Capital Management
  • Innoviva
  • Samsung NEXT

Beacon Biosignals Overview

About Beacon Biosignals

Beacon Biosignals is a Boston-headquartered neurotechnology firm offering FDA-cleared wearable EEG headbands for clinical trials in sleep disorders and brain diseases. The Waveheadband captures high-resolution brainwave data during polysomnography and ambulatory monitoring, processed by cloud AI to derive biomarkers for Alzheimer's progression and insomnia severity. Beacon Biosignals serves pharma clients like Biogen in patient selection for trials, analyzing petabytes of neural signals from studies in North America and Europe.


Founded

2019

HQ

United StatesBoston, MA

Website

beacon.bio

Status

Privately held

Customer focus

B2B

Revenue model

Product sales, Subscription

Beacon Biosignals Funding History

Beacon Biosignals has raised a total of $127M across 4 funding rounds.

Beacon Biosignals' first fundraising round was a $3M seed round in June 2019. The most recent completed round was a $11M Series B in April 2026.

Beacon Biosignals funding rounds

Beacon Biosignals funding rounds
DateStageInvestorsRaisedDeal Summary
Apr 2026Series BPalo Santo Fund (lead); General Catalyst; Samsung NEXT; Logos Capital; GV; Casdin Capital; S32; Catalio Capital Management; JSL Health Capital; Innoviva; Indicator Ventures; Kicker Ventures$11M-
Nov 2025Series BCatalio Capital Management (lead); GV (lead); Innoviva (lead); Nexus NeuroTech (lead); S32 (lead); Takeda Pharmaceuticals; General Catalyst; Casdin Capital; Logos Capital; Indicator Ventures$86MBeacon Biosignals, a neurotechnology company based in Boston, develops an AI-driven platform for brain health diagnostics using its FDA-cleared Waveband device, which measures EEG during sleep and wake to capture longitudinal brain function data at home. The platform combines this data with machine learning to generate biomarkers for neurological, psychiatric, and sleep disorders like depression, Parkinson’s, Alzheimer’s, and sleep apnea, supporting clinical trials, therapeutic development, and digital diagnostics for pharma and med-tech partners. On November 13, 2025, Beacon Biosignals closed an oversubscribed $86 million Series B funding round, co-led by Catalio Capital Management, GV (Google Ventures), Innoviva, Nexus NeuroTech, and S32, with participation from Takeda and returning investors General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. This brought total funding to over $121 million. The capital will expand the world’s largest neurodiagnostic dataset, advance AI-derived biomarkers, scale at-home EEG and sleep monitoring, and accelerate commercialization and clinical adoption. Beacon’s technology differentiates from consumer wearables by providing direct, gold-standard EEG data, fueling a foundation model trained on millions of hours of recordings to detect early disease signatures and predict treatment responses. Recent developments include expanding a Takeda partnership for narcolepsy programs, where milestones depend on data advancing clinical outcomes rather than hardware sales, and acquiring CleveMed, a home sleep testing specialist, in April 2025. The company positions itself across the neurotech stack, from sensing and data layers to AI biomarkers and pharma integration.
Nov 2021Series AGeneral Catalyst (lead); Andrew Beck; Casdin Capital; Indicator Ventures$27MBeacon Biosignals is a neurotechnology company that applies artificial intelligence to EEG data to develop computational biomarkers for neurology, psychiatry, and sleep medicine, enabling precision medicine for brain conditions. The company announced an oversubscribed $27 million Series A financing on November 8, 2021, led by General Catalyst with participation from Casdin Capital, existing seed investors, and new angel investors including Andy Beck, CEO of PathAI. This round brought total funding to $30 million, with proceeds aimed at scaling its EEG neurobiomarker discovery platform to support biopharma clinical trials with quantitative endpoints, safety tools, and diagnostics. As part of the deal, Robin Washington, former CFO of Gilead and board member at Alphabet, Salesforce, and Honeywell, joined the board. Beacon's platform processes EEG data from any source to provide mechanistic insights in phase 1 trials, characterize dose-related neuroactivity, and identify novel endpoints. General Catalyst's Hemant Taneja highlighted Beacon's position to translate machine learning into clinical benefits for predictive brain health analytics. The company has traction with biopharma partners for clinical development programs. Subsequent rounds include an $86 million Series B in 2025 co-led by Innoviva, GV, Nexus NeuroTech, Section 32, and Catalio Capital, with participation from Takeda and returning investors like General Catalyst, Casdin Capital, and Indicator Ventures, bringing total funding over $121 million. This funded expansion of its FDA-cleared Waveband system and neurodiagnostic dataset for conditions like depression, Parkinson's, Alzheimer's, and sleep apnea. In April 2025, Beacon acquired home sleep testing firm CleveMed.
Jun 2019SeedHalf Court Ventures$3M-

Who has invested in Beacon Biosignals?

17 investors have backed Beacon Biosignals across its funding rounds, including General Catalyst, Casdin Capital, Indicator Ventures, GV, S32 and Catalio Capital Management.

Lead investors include Palo Santo Fund, Catalio Capital Management, GV, Innoviva, Nexus NeuroTech and 2 other investors.


Beacon Biosignals Investors

Investors in Beacon Biosignals by funding rounds participated
InvestorHQRoundsRoleFirst check
General CatalystUnited StatesSan Francisco, CA3LeadNov 2021
Casdin CapitalUnited StatesNew York City, NY3ParticipantNov 2021
Indicator VenturesUnited StatesNew York City, NY3ParticipantNov 2021
GVUnited StatesSan Francisco, CA2LeadNov 2025
S32United StatesSan Diego, CA2LeadNov 2025
Catalio Capital ManagementUnited StatesNew York City, NY2LeadNov 2025
InnovivaUnited StatesUnited States2LeadNov 2025
Takeda PharmaceuticalsJapanTokyo1ParticipantNov 2025
Andrew BeckUnited StatesUnited States1ParticipantNov 2021
Samsung NEXTUnited StatesSan Francisco, CA1ParticipantApr 2026
Half Court VenturesUnited StatesBoston, MA1ParticipantJun 2019
Logos CapitalUnited StatesMiami, FL1ParticipantApr 2026
Logos CapitalUnited StatesSan Francisco, CA1ParticipantNov 2025

This data is available for Pro users. Sign up to see all 17 Beacon Biosignals investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Beacon Biosignals

Beacon Biosignals has acquired 2 companies to date.

Last acquisition by Beacon Biosignals was on April 21st 2025. Beacon Biosignals acquired CleveMed for undisclosed valuation.


Latest Acquisitions by Beacon Biosignals

CleveMed
Dreem (R&D unit)
Description
CleveMed is a Cleveland-headquartered developer of wireless medical devices focused on sleep diagnostics and portable monitoring. The company produces the BioRadio telemetry system and PSGLite home sleep apnea testing devices that enable full polysomnography outside clinical settings. Its solutions integrate EEG, EMG, ECG, and airflow sensors for research and patient care in neurology and pulmonology worldwide.
Dreem's R&D unit develops sleep monitoring systems for home use. The Paris-based neurotechnology team creates wearable devices that track brainwaves and sleep patterns through dreem.com.
HQ CountryUnited StatesFrance
HQ City
Cleveland, OH
Paris
Deal Date21 Apr 202511 Jul 2023
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Beacon Biosignals acquisitions and their M&A valuation multiples.

Start Free Trial

Beacon Biosignals Competitors

Beacon Biosignals competitors include listed companies like Tempus AI and SAP, and private ones like Commure, Abridge, Sword Health and Astromech.

Public and private companies comparable to Beacon Biosignals
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$15B10.1x
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x
AbridgeUnited StatesPittsburgh, PAPrivate$117M-$5.3B45.3x
Sword HealthUnited StatesNew York City, NYPrivate$240M-$4B16.7x
AstromechUnited StatesUnited StatesPrivate--$3.8B-
SAPGermanyGermanyPublicly listed$42B$13B$248B5.4x

Beacon Biosignals Public Comps

Beacon Biosignals is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, CrowdStrike, SAP, Thermo Fisher Scientific, Siemens, Salesforce, Abbott and Danaher.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Samsung$243B$67B4.4x2.4x15.8x4.4x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
Roche$77B$26B5.0x4.9x14.6x12.4x
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x
SAP$42B$13B5.8x5.4x18.4x17.1x
Thermo Fisher Scientific$45B$11B6.3x6.0x26.8x23.6x
Siemens$91B$15B3.0x2.9x18.1x15.7x
Salesforce$42B$13B5.5x5.2x17.8x12.2x

This data is available for Pro users. Sign up to see all Beacon Biosignals competitors and their valuation data.

Start Free Trial

Common questions about Beacon Biosignals

When was Beacon Biosignals founded?Beacon Biosignals was founded in 2019.
Where is Beacon Biosignals headquartered?Beacon Biosignals is headquartered in Boston, MA, United States.
Is Beacon Biosignals publicly listed?No, Beacon Biosignals is a private, VC-backed company.
How much funding has Beacon Biosignals raised?Beacon Biosignals has raised $127M across 4 funding rounds.
What was Beacon Biosignals' last funding round?Beacon Biosignals' last funding round was a $11M Series B in April 2026, led by Palo Santo Fund.
Who are Beacon Biosignals' investors?Beacon Biosignals' investors include General Catalyst, Casdin Capital, Indicator Ventures, GV, S32, Catalio Capital Management, Innoviva, Takeda Pharmaceuticals, Andrew Beck, Samsung NEXT and 7 others.
Which companies are comparable to Beacon Biosignals?Companies comparable to Beacon Biosignals include Tempus AI, Commure, Abridge, Sword Health, Astromech and SAP.
How many companies has Beacon Biosignals acquired?Beacon Biosignals has acquired 2 companies, including CleveMed and Dreem (R&D unit).

See companies similar to Beacon Biosignals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial